Abstract：
Lobomycosis is a chronic disease caused by Lacazia loboi, which is endemic to the Amazon rainforest, where it affects forest dwellers in Brazil. There is no disease control program and no official therapeutic protocol. This situation contributes to an unknown disease prevalence and unmet needs of people disabled by this disease who seek access to treatment. This review provides an update on the subject with an emphasis on therapeutic advances in humans. All relevant studies that addressed epidemiology, diagnosis, or therapeutics of lobomycosis were considered. Seventy-one articles published between 1931 and 2021 were included for a narrative literature review on the epidemiology and quest for a cure. An effective therapy for lobomycosis has been found following decades of research led by the State Dermatology Program of Acre in the Amazon rainforest, where the largest number of cases occur. This discovery opened new avenues for future studies. The main recommendations here, addressed to the Brazilian Ministry of Health, are for lobomycosis to become a reportable disease to ensure that disease prevalence is measured, and that it be prioritized such that affected individuals may access treatment free-of-charge.
摘要：
白霉菌病是由Lacazialoboi引起的慢性疾病，这是亚马逊雨林特有的，它影响了巴西的森林居民。没有疾病控制计划，也没有官方的治疗方案。这种情况导致未知的疾病患病率和因寻求治疗而致残的人的需求未得到满足。这篇综述提供了有关该主题的最新信息，重点是人类的治疗进展。所有涉及流行病学的相关研究，诊断,或叶真菌病的治疗被认为。纳入了1931年至2021年之间发表的71篇文章，以进行有关流行病学和寻求治疗方法的叙述性文献综述。在亚马逊热带雨林的Acre国家皮肤病学计划领导的数十年研究之后，已经发现了一种有效的大叶真菌病疗法，发生病例最多的地方。这一发现为未来的研究开辟了新的途径。这里的主要建议，致巴西卫生部，使大孢子菌病成为可报告的疾病，以确保疾病患病率得到测量，并优先考虑受影响的个人可以免费获得治疗。
